Back

Thiogenesis Therapeutics engages Brisco Capital Partners to enhance investor communications

Verifying
  • Thiogenesis Therapeutics engaged Brisco Capital Partners to improve investor communications.
  • Brisco Capital Partners will receive a monthly fee and stock options.
  • The engagement includes raising awareness of Thiogenesis Therapeutics’ rare disease drug programs.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Thiogenesis Therapeutics engages Brisco Capital Partners to enhance investor communications - CoinPost Terminal